chr9-95453599-C-T
Variant summary
Our verdict is Uncertain significance. The variant received 1 ACMG points: 2P and 1B. PM2BP6
The NM_000264.5(PTCH1):c.3328G>A(p.Asp1110Asn) variant causes a missense change. The variant allele was found at a frequency of 0.00000274 in 1,461,546 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D1110Y) has been classified as Uncertain significance.
Frequency
Consequence
NM_000264.5 missense
Scores
Clinical Significance
Conservation
Publications
- basal cell nevus syndrome 1Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
- holoprosencephaly 7Inheritance: AD Classification: DEFINITIVE, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), G2P
- nevoid basal cell carcinoma syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Orphanet
- holoprosencephalyInheritance: AD Classification: LIMITED Submitted by: Illumina
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 1 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000264.5. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PTCH1 | NM_000264.5 | MANE Select | c.3328G>A | p.Asp1110Asn | missense | Exon 20 of 24 | NP_000255.2 | ||
| PTCH1 | NM_001083603.3 | MANE Plus Clinical | c.3325G>A | p.Asp1109Asn | missense | Exon 20 of 24 | NP_001077072.1 | ||
| PTCH1 | NM_001354918.2 | c.3172G>A | p.Asp1058Asn | missense | Exon 19 of 23 | NP_001341847.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PTCH1 | ENST00000331920.11 | TSL:5 MANE Select | c.3328G>A | p.Asp1110Asn | missense | Exon 20 of 24 | ENSP00000332353.6 | ||
| PTCH1 | ENST00000437951.6 | TSL:5 MANE Plus Clinical | c.3325G>A | p.Asp1109Asn | missense | Exon 20 of 24 | ENSP00000389744.2 | ||
| PTCH1 | ENST00000429896.6 | TSL:1 | c.2875G>A | p.Asp959Asn | missense | Exon 20 of 24 | ENSP00000414823.2 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome AF: 0.00000274 AC: 4AN: 1461546Hom.: 0 Cov.: 31 AF XY: 0.00000413 AC XY: 3AN XY: 727092 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:1
The p.D1110N variant (also known as c.3328G>A), located in coding exon 20 of the PTCH1 gene, results from a G to A substitution at nucleotide position 3328. The aspartic acid at codon 1110 is replaced by asparagine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Gorlin syndrome Benign:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at